secwatch / observer
8-K filed September 26, 2023, 7:59 PM ET CIK 0001358762
M&A confidence high sentiment positive materiality 1.00

REATA PHARMACEUTICALS INC: M&A transaction — Reata acquired by Biogen; shareholders receive $172.50/share cash

REATA PHARMACEUTICALS INC

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dawn C. Bir

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Departed

Martin W. Edwards, M.D.

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
At the Effective Time, each of Martin W. Edwards, M.D., William D. McClellan, Jr. and R. Kent McGaughy Jr., resigned as a director of the Company.
Departed

Manmeet S. Soni

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Departed

J. Warren Huff

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
Departed

Andrea L. Loewen

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Appointed

Robin Kramer

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
At the Effective Time, each of Fearghas Carruthers, Michael Dambach and Robin Kramer became a director of Reata.
Departed

Shamim Ruff

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
Departed

Seemi Khan, M.D.

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Departed

Bhaskar Anand

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Departed

Steven W. Ryder

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
Departed

J. Warren Huff

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Departed

R. Kent McGaughy Jr.

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
At the Effective Time, each of Martin W. Edwards, M.D., William D. McClellan, Jr. and R. Kent McGaughy Jr., resigned as a director of the Company.
Departed

Rajiv Patni, M.D.

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Departed

William E. Rose

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
Departed

Michael D. Wortley

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Appointed

Michael Dambach

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
At the Effective Time, each of Fearghas Carruthers, Michael Dambach and Robin Kramer became a director of Reata.
Departed

Christy J. Oliger

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
Departed

Colin J. Meyer, M.D.

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Departed

William D. McClellan, Jr.

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
At the Effective Time, each of Martin W. Edwards, M.D., William D. McClellan, Jr. and R. Kent McGaughy Jr., resigned as a director of the Company.
Appointed

Fearghas Carruthers

Director
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
At the Effective Time, each of Fearghas Carruthers, Michael Dambach and Robin Kramer became a director of Reata.
Departed

Dakota Gallivan

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Departed

W. Christian Wigley, Ph.D.

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
Departed

Steve Harman

Other Named Officer
REATA PHARMACEUTICALS INC
Effective
2023-09-26
Filed
September 26, 2023, 7:59 PM ET
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dawn C. Bir was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Martin W. Edwards, M.D. resigned as Director at REATA PHARMACEUTICALS INC.

Action
resigned
Role
Director
Exact text from the filing
At the Effective Time, each of Martin W. Edwards, M.D., William D. McClellan, Jr. and R. Kent McGaughy Jr., resigned as a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Manmeet S. Soni was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

J. Warren Huff resigned as Director at REATA PHARMACEUTICALS INC.

Action
resigned
Role
Director
Exact text from the filing
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Andrea L. Loewen was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Robin Kramer was appointed as Director at REATA PHARMACEUTICALS INC.

Action
became a director
Role
Director
Exact text from the filing
At the Effective Time, each of Fearghas Carruthers, Michael Dambach and Robin Kramer became a director of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Shamim Ruff resigned as Director at REATA PHARMACEUTICALS INC.

Action
resigned
Role
Director
Exact text from the filing
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Seemi Khan, M.D. was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Bhaskar Anand was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Steven W. Ryder resigned as Director at REATA PHARMACEUTICALS INC.

Action
resigned
Role
Director
Exact text from the filing
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

J. Warren Huff was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

R. Kent McGaughy Jr. resigned as Director at REATA PHARMACEUTICALS INC.

Action
resigned
Role
Director
Exact text from the filing
At the Effective Time, each of Martin W. Edwards, M.D., William D. McClellan, Jr. and R. Kent McGaughy Jr., resigned as a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Rajiv Patni, M.D. was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

William E. Rose resigned as Director at REATA PHARMACEUTICALS INC.

Action
resigned
Role
Director
Exact text from the filing
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael D. Wortley was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Dambach was appointed as Director at REATA PHARMACEUTICALS INC.

Action
became a director
Role
Director
Exact text from the filing
At the Effective Time, each of Fearghas Carruthers, Michael Dambach and Robin Kramer became a director of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Christy J. Oliger resigned as Director at REATA PHARMACEUTICALS INC.

Action
resigned
Role
Director
Exact text from the filing
Effective as of immediately following the Effective Time, each of J. Warren Huff, Christy J. Oliger, William E. Rose, Shamim Ruff and Steven W. Ryder also resigned as a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Colin J. Meyer, M.D. was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

William D. McClellan, Jr. resigned as Director at REATA PHARMACEUTICALS INC.

Action
resigned
Role
Director
Exact text from the filing
At the Effective Time, each of Martin W. Edwards, M.D., William D. McClellan, Jr. and R. Kent McGaughy Jr., resigned as a director of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Fearghas Carruthers was appointed as Director at REATA PHARMACEUTICALS INC.

Action
became a director
Role
Director
Exact text from the filing
At the Effective Time, each of Fearghas Carruthers, Michael Dambach and Robin Kramer became a director of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dakota Gallivan was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

W. Christian Wigley, Ph.D. was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Steve Harman was removed as other_named_officer at REATA PHARMACEUTICALS INC.

Action
removed
Exact text from the filing
Additionally, effective as of immediately following the Effective Time, each of J. Warren Huff, Manmeet S. Soni, Dawn C. Bir, Colin J. Meyer, M.D., Rajiv Patni, M.D., Michael D. Wortley, Bhaskar Anand, Steve Harman, Seemi Khan, M.D., Andrea L. Loewen, W. Christian Wigley, Ph.D. and Dakota Gallivan was removed as an officer of Reata.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

REATA PHARMACEUTICALS INC: Amended and restated certificate of incorporation and bylaws effective upon merger.

Change
fiscal year change
Exact text from the filing
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information set forth in the section above titled “Introduction” of this Current Report on Form 8-K is incorporated herein by reference. Copies of the Amended and Restated Certificate of Incorporation, the Amended and Restated Bylaws, the Second Amended and Restated Certificate of Incorporation and the Second Amended and Restated Bylaws are filed as Exhibits 3.1, 3.2, 3.3 and 3.4, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
View on SEC.gov
M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

REATA PHARMACEUTICALS INC underwent a change of control involving Biogen Inc. for $172.50 in cash (closed 2023-09-26).

Action
change of control
Counterparty
Biogen Inc.
Consideration
$172.50 in cash
Closing
2023-09-26
Exact text from the filing
the Reata Common Stock with respect to which statutory rights of appraisal were properly and validly demanded) was automatically canceled and converted into the right to receive $172.50 in cash, without interest and subject to any applicable withholding taxes (the “ Merger Consideration ”). In addition, effective as of immediately prior to the Effective Time, (i)
View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR
accession 0001193125-23-242619
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.